Divergence Neuro
Jeff Moore has extensive work experience in various leadership roles within the technology industry. Jeff is currently the Chief Executive Officer at ReMendIt Inc. since November 2022. Prior to this, they served as an Investor, Board Member, and COO at Divergence Neuro starting from June 2021. Before that, they held the position of Chief Executive Officer at JM Tech Labs Inc. from May 2021.
Earlier in their career, Jeff held multiple roles at Trapeze Group, including VP of Sales, VP of Industry Solutions and Alliances, Director of Industry Solutions and Alliances, VP of Product Development and Delivery, and Director of Technology Development. Jeff worked at Trapeze Group from 2014 to 2020.
Jeff also has experience working as the Director of Professional Services at Dundas Data Visualization Inc. from June 2013 to July 2014. Prior to that, they held various positions at Trapeze Group, including Manager of Technical Delivery, Technical Team Lead, and Technical Product Specialist, starting from 2006.
Jeff's early career includes a role as a Business Analyst at Hewlett-Packard in 2005. Overall, Jeff Moore has a strong background in technology leadership and management, gaining experience in various organizations throughout their career.
Jeff Moore attended Wilfrid Laurier University from 2001 to 2006. During this time, they obtained a Bachelor of Science degree in Computing and Computer Electronics as well as a Bachelor of Business Administration degree in Business Administration.
This person is not in any teams
Divergence Neuro
Divergence is a mobile, cloud-based, AI-driven mental health technology platform that connects therapists and patients through smart relational technologies to achieve better outcomes in mental health care. Our platform provides a user-friendly, portable, and insightful service to enable mental health care providers to easily design, drive, andmeasure the outcome of mental health care with the help of advanced EEG analytics and Machine Learning predictive biomarker technologies. We provide the platform as a service for mental health care providers servicing those who are afflicted with addiction, depression, PTSD, anxiety, and ASD. Divergence also works with pharmaceutic technology companies to help validate the effectiveness of their compounds and treatments with neuroscience, ML and AI. In particular, we help companies that work with novel psychedelic therapy to validate the effects of their drugs and therapies by building biomarker model with EEG data in our research platform.